Published in Lung Cancer on August 17, 2006
Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging (2013) 0.95
FDG PET/CT metabolic tumour volume in small-cell lung cancer: better staging and prognostic stratification for an improved therapeutic strategy. Eur J Nucl Med Mol Imaging (2012) 0.87
Prognostic significance of 18 F-fluorodeoxyglucose - positron emission tomography after treatment in patients with limited stage small cell lung cancer. Clin Med Res (2008) 0.84
PET/CT imaging in response evaluation of SCLC patients. Lung Cancer (2006) 0.75
Multiple pulmonary nodules with high metabolic activity: Potential benefit of multiple nodule biopsies by video-assisted thoracic surgery: A case report. Exp Ther Med (2013) 0.75
Preoperative staging of lung cancer with combined PET-CT. N Engl J Med (2009) 7.38
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol (2007) 3.99
Patterns of care in the management of seminoma stage I: results from a European survey. BJU Int (2012) 3.41
Detection of pulmonary embolism with combined ventilation-perfusion SPECT and low-dose CT: head-to-head comparison with multidetector CT angiography. J Nucl Med (2009) 3.12
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med (2015) 3.05
Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer (2004) 3.04
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood (2005) 2.92
CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax (2012) 2.81
A classical brown adipose tissue mRNA signature partly overlaps with brite in the supraclavicular region of adult humans. Cell Metab (2013) 2.54
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2010) 2.48
The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. J Thorac Oncol (2009) 2.48
Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. Thorax (2010) 2.44
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica (2006) 1.98
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol (2009) 1.95
Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol (2012) 1.93
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol (2009) 1.70
Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol (2004) 1.68
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail (2005) 1.64
Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial. Eur J Nucl Med Mol Imaging (2011) 1.63
Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol (2002) 1.61
Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck (2008) 1.49
Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J Heart Lung Transplant (2007) 1.48
HIV infection and arterial inflammation assessed by (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET): a prospective cross-sectional study. J Nucl Cardiol (2014) 1.46
Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging (2006) 1.46
18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res (2010) 1.45
[Lung cancer--should positron-emission tomography be used?]. Ugeskr Laeger (2004) 1.38
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
[Patients with acute critical pulmonary embolism should be evaluated and treated in a centre with medical and surgical possibilities]. Ugeskr Laeger (2013) 1.37
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol (2004) 1.33
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol (2010) 1.31
Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med (2010) 1.27
Diagnostic procedures for submucosal tumors in the gastrointestinal tract. World J Gastroenterol (2007) 1.16
Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. Am J Nucl Med Mol Imaging (2013) 1.15
Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol (2010) 1.15
MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study. Gynecol Oncol (2012) 1.14
Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1. J Heart Lung Transplant (2009) 1.14
Comparison of V/Q SPECT and planar V/Q lung scintigraphy in diagnosing acute pulmonary embolism. Nucl Med Commun (2010) 1.12
The diagnostic value of PET/CT for primary ovarian cancer--a prospective study. Gynecol Oncol (2007) 1.10
Need for intensive histopathologic analysis to determine lymph node metastases when using sentinel node biopsy in oral cancer. Laryngoscope (2008) 1.10
The diagnostic and prognostic value of ¹⁸F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging (2012) 1.09
Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant (2012) 1.08
Pulmonary radioaerosol mucociliary clearance in diagnosis of primary ciliary dyskinesia. Chest (2007) 1.07
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.06
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol (2014) 1.05
Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes Cancer (2008) 1.05
How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging (2006) 1.03
A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist (2012) 1.03
Clinical evaluation of PET image reconstruction using a spatial resolution model. Eur J Radiol (2012) 1.02
Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med (2014) 1.01
Outcome of lung transplanted patients with primary graft dysfunction. Eur J Cardiothorac Surg (2006) 1.01
The role of SPECT-CT in the lymphoscintigraphic identification of sentinel nodes in patients with oral cancer. Acta Otolaryngol (2006) 1.01
18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review. Oncologist (2011) 1.00
Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med (2012) 0.99
Changes in lung function of HIV-infected patients: a 4.5-year follow-up study. Clin Physiol Funct Imaging (2012) 0.98
Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol (2002) 0.97
The influence of platelets, plasma and red blood cells on functional haemostatic assays. Blood Coagul Fibrinolysis (2011) 0.97
Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer (2002) 0.97
Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica (2011) 0.96
A genome-wide association study of men with symptoms of testicular dysgenesis syndrome and its network biology interpretation. J Med Genet (2011) 0.96
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta Oncol (2013) 0.96
The prevalence of occult metastases in nonsentinel lymph nodes after step-serial sectioning and immunohistochemistry in cN0 oral squamous cell carcinoma. Laryngoscope (2011) 0.95
Treatment of advanced non-small cell lung cancer. BMJ (2002) 0.95
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS (2010) 0.95
PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum (2007) 0.94
Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opin Pharmacother (2011) 0.93
Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy. Acta Oncol (2007) 0.93
First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience. Acta Oncol (2011) 0.93
Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol (2006) 0.92
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood (2014) 0.92
Liver metastases from colorectal cancer: imaging with superparamagnetic iron oxide (SPIO)-enhanced MR imaging, computed tomography and positron emission tomography. Abdom Imaging (2007) 0.92
A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol (2012) 0.91
The pituitary-Leydig cell axis before and after orchiectomy in patients with stage I testicular cancer. Eur J Cancer (2011) 0.90
Hyperpolarized 3He MRI and 81mKr SPECT in chronic obstructive pulmonary disease. Eur J Nucl Med Mol Imaging (2004) 0.90
Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older. Cancer (2013) 0.89
No AZF deletion in 160 patients with testicular germ cell neoplasia. Mol Hum Reprod (2003) 0.89
PET/MRI in cancer patients: first experiences and vision from Copenhagen. MAGMA (2012) 0.89
Personalized oncology: genomic screening in phase 1. APMIS (2014) 0.89